[Federal Register Volume 67, Number 179 (Monday, September 16, 2002)]
[Notices]
[Pages 58448-58449]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: C2-19331]
-----------------------------------------------------------------------
DEPARTMENT OF VETERANS AFFAIRS
38 CFR Part 4
RIN 2900-AF00
Schedule for Rating Disabilities; the Skin
Correction
In rule document 02-19331 beginning on page 49590 in the issue of
Wednesday, July 31, 2002 make the following correction:
Sec. 4.118 [Corrected]
1. On page 49596, the Rate Schedule for 7802 is corrected to read
as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7802 Scars, other than head, face, or neck, that are
superficial and that do not cause limited motion:.........
Area or areas of 144 square inches (929 sq. cm.) or 10
greater...............................................
Note (1): Scars in widely separated areas, as on two or
more extremities or on anterior and posterior surfaces
of extremities or trunk, will be separately rated and
combined in accordance with Sec. 4.25 of this part.
Note (2): A superficial scar is one not associated with
underlying soft tissue damage.
------------------------------------------------------------------------
2. On the same page, the Rate Schedule for 7807, 7808 and 7809 is
corrected to read as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7807 American (New World) leishmaniasis (mucocutaneous,
espundia):
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or dermatitis (DC 7806), depending upon the
predominant disability................................
Note: Evaluate non-cutaneous (visceral) leishmaniasis
under DC 6301 (visceral leishmaniasis).
7808 Old World leishmaniasis (cutaneous, Oriental sore):
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's, 7801, 7802, 7803, 7804, or 7805),
or dermatitis (DC 7806), depending upon the
predominant disabililty...............................
Note: Evaluate non-cutaneous (visceral) leishmaniasis
under DC 6301 (visceral leishmaniasis).
7809 Discoid lupus erythematosus or subacute cutaneous
lupus erythematosus:
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or dermatitis (DC 7806), depending upon the
predominant disability. Do not combine with ratings
under DC 6350.........................................
------------------------------------------------------------------------
3. On page 49597, the Rate Schedule for 7811 is corrected to read
as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7811 Tuberculosis luposa (lupus vulgaris), active or
inactive:
Rate under Sec. Sec. 4.88c or 4.89, whichever is
appropriate...........................................
------------------------------------------------------------------------
[[Page 58449]]
4. On the same page, the Rate Schedule for 7813 is corrected to
read as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7813 Dermatophytosis (ringworm: of body, tinea corporis; of
head, tinea capitis; of feet, tinea pedis; of beard area,
tinea barbae; of nails, tinea unguium; of inguinal area
(jock itch), tinea cruris):
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or dermatitis (DC 7806), depending upon the
predominant disability................................
------------------------------------------------------------------------
5. On the same page, the Rate Schedule for 7818, 7819, and 7820 is
corrected to read as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7818 Malignant skin neoplasms (other than malignant
melanoma):
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or impairment of function.............................
Note: If a skin malignancy requires therapy that is
comparable to that used for systemic malignancies,
i.e., systemic chemotherapy, X-ray therapy more
extensive than to the skin, or surgery more extensive
than wide local excision, a 100-percent evaluation
will be assigned from the date of onset of treatment,
and will continue, with a mandatory VA examination six
months following the completion of such antineoplastic
treatment, and any change in evaluation based upon
that or any subsequent examination will be subject to
the provisions of Sec. 3.105(e) of this chapter. If
there has been no local recurrence or metastasis,
evaluation will then be made on residuals. If
treatment is confined to the skin, the provisions for
a 100-percent evaluation do not apply.
7819 Benign skin neoplasms:
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or impairment of function.............................
7820 Infections of the skin not listed elsewhere (including
bacterial, fungal, viral, treponemal and parasitic
diseases):
Rate as disfigurement of the head, face, or neck (DC
7800), scars (DC's 7801, 7802, 7803, 7804, or 7805),
or dermatitis (DC 7806), depending upon the
predominant disability................................
------------------------------------------------------------------------
6. On page 49599, the Rate Schedule for 7833 is corrected to read
as follows:
------------------------------------------------------------------------
Rating
------------------------------------------------------------------------
7833 Malignant melanoma:
Rate as scars (DC's 7801, 7802, 7803, 7804, or 7805),
disfigurement of the head, face, or neck (DC 7800), or
impairment of function (under the appropriate body
system)...............................................
Note: If a skin malignancy requires therapy that is
comparable to that used for systemic malignancies,
i.e., systemic chemotherapy, X-ray therapy more
extensive than to the skin, or surgery more extensive
than wide local excision, a 100-percent evaluation
will be assigned from the date of onset of treatment,
and will continue, with a mandatory VA examination six
months following the completion of such antineoplastic
treatment, and any change in evaluation based upon
that or any subsequent examination will be subject to
the provisions of Sec. 3.105(e). If there has been
no local recurrence or metastasis, evaluation will
then be made on residuals. If treatment is confined to
the skin, the provisions for a 100-percent evaluation
do not apply.
------------------------------------------------------------------------
[FR Doc. C2-19331 Filed 9-13-02; 8:45 am]
BILLING CODE 1505-01-D
